PTC Therapeutics (PTCT) – PRNewswire
-
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
-
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
-
PTC Therapeutics Provides Key Regulatory Updates
-
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
PTC Therapeutics to Participate at Upcoming Investor Conferences
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
-
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure
-
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference
-
PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results
-
PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion
-
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results
-
PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
-
CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
-
PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
-
PTC Therapeutics to Participate at Upcoming Investor Conferences
-
PTC Therapeutics to Present Recent Data for Sepiapterin at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
-
PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results
-
CHMP Recommends Evrysdi® for Babies Under Two Months Old with Spinal Muscular Atrophy
-
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial Results
-
PTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer
-
PTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin
-
PTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures
-
PTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
PTC Therapeutics to Participate at Upcoming Investor Conferences
-
PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial
-
PTC Therapeutics Announces Strategic Pipeline Prioritization
-
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
-
PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
-
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2023 Financial Results
-
PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics
-
PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-
PTC Therapeutics to Participate at Upcoming Investor Conferences
-
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
-
PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation
-
PTC Therapeutics to Participate at Upcoming Investor Conference
-
NICE Recommends Reimbursement for Translarna™
-
PTC Therapeutics Launches 9th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community
-
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 41st Annual J.P. Morgan Healthcare Conference
-
PTC Therapeutics to Participate at 41st Annual J.P. Morgan Healthcare Conference
Back to PTCT Stock Lookup
